Literature DB >> 7795309

The role of N-acetylcystein administration on the oxidative response of neutrophils during cardiopulmonary bypass.

L W Andersen1, J Thiis, A Kharazmi, I Rygg.   

Abstract

The role of N-acetylcystein (NAC) administration on the oxidative response of neutrophils during cardiopulmonary bypass (CPB) was evaluated in a double-blind study. Twenty-four adult patients undergoing coronary artery bypass were included in the study. Twelve patients received NAC as a bolus of 100 mg/kg followed by a continuous infusion of 20 mg/kg/h in the bypass circuit from the beginning to the end of bypass. A further 12 patients received placebo. Citrated blood samples for measurement of oxidative burst response of neutrophils were obtained at different time points during bypass. The oxidative burst response of neutrophils in the patients receiving NAC was significantly low at all times during bypass. Based on these findings NAC appears to act as an oxygen free radical scavenger during open-heart surgery.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7795309     DOI: 10.1177/026765919501000105

Source DB:  PubMed          Journal:  Perfusion        ISSN: 0267-6591            Impact factor:   1.972


  3 in total

1.  N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid.

Authors:  W A De Backer; B Amsel; P G Jorens; L Bossaert; P S Hiemstra; P van Noort; F J van Overveld
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

2.  Effects of N-acetylcysteine on myocardial ischemia-reperfusion injury in bypass surgery.

Authors:  Gokcen Orhan; Nihan Yapici; Meral Yuksel; Murat Sargin; Sahin Senay; A Süha Yalçin; Zuhal Aykaç; Serap Aykut Aka
Journal:  Heart Vessels       Date:  2006-01       Impact factor: 1.814

Review 3.  N-acetylcysteine for sepsis and systemic inflammatory response in adults.

Authors:  Tamas Szakmany; Balázs Hauser; Peter Radermacher
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.